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Purpose of the review 
Barth syndrome is an X-linked disease characterised by defective remodelling of 
phospholipid side chains in mitochondrial membranes. Major features include 
neutropenia, dilated cardiomyopathy, motor delay and proximal myopathy, feeding 
problems and constitutional growth delay.  We conducted this review of neutropenia in 
Barth syndrome to aid in the diagnosis of this disease, and to improve understanding of 
both the consequences of neutropenia and the benefits of treatment with granulocyte 
colony-stimulating factor (G-CSF). 
 
Recent findings 
In 88 patients with Barth syndrome, neutropenia, i.e. at least one count below 1.5 x 
109/L, was detected in 74 (84%) and 44% had severe chronic neutropenia, with multiple 
counts below 0.5 x 109/L.  The pattern of neutropenia varied between intermittent and 
unpredictable, chronic and severe, or cyclical with mathematically regular oscillations.  
Monocytosis, i.e., monocytes >1.0 x 109/L, was observed at least once in 64 of 85 
(75%) patients. Granulocyte colony stimulating factor (G-CSF) was administered to 39 
of 88 subjects (44%). Weekly average G-CSF doses ranged from 0.12 to 10.92 
mcg/kg/day (mean 1.16 mcg/kg/day, median 1.16 mcg/kg/day). Antibiotic prophylaxis 
was additionally employed in 21 of 26 neutropenic patients. Pre-treatment bone marrow 
evaluations predominantly showed reduced myeloid maturation which normalised on G-
CSF therapy in seven of 13 examined. Consistent clinical improvement, with reduced 
signs and symptoms of infections, was observed in response to prophylactic G-CSF ± 
prophylactic antibiotics. However, despite G-CSF and antibiotics, one adult patient died 
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with multiple infections related to indwelling medical devices and gastrostomy site 
infection after 15.5 years on G-CSF and a paediatric patient required gastrostomy 
removal for recurrent abdominal wall cellulitis. 
 
Summary:   
Barth syndrome should be considered in any male with neutropenia accompanied by 
any of the characteristic features of this syndrome. Prophylaxis with G-CSF ± antibiotics 
prevents serious bacterial infections in the more severe neutropenic patients although 
infections remain a threat even in patients who are very compliant with therapy, 
especially in those with indwelling devices.  
 
Keywords 
Granulocytes, Monocytes, Macrophages; Barth Syndrome; Granulocyte Colony-
Stimulating Factor; Neutropenia 
 
 
 
 
Background 
Peter Barth first reported the syndrome which carries his name in 1983 as an X-linked 
triad of dilated cardiomyopathy (DCM), skeletal myopathy and neutropenia with high 
mortality. He described three affected male infants from a large Dutch family in which 17 
boys had died at between three days and 31 months of age due to either neutropenic 
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bacterial sepsis or cardiac failure.[1] He subsequently reported cyclic neutropenia and 
monocytosis.[2] The phenotype of Barth syndrome (BTHS) has expanded steadily and 
now includes developmental motor and constitutional growth delay, organic aciduria, 
cardiac endocardial fibroelastosis (EFE) and left ventricular non-compaction (LVNC), 
ventricular arrhythmia, fetal cardiomyopathy/fetal loss, feeding problems, hypoglycemia, 
lactic acidosis and characteristic facial features (reviewed in [3]). 
 
Mutations in TAZ (Xq28) as the cause for BTHS were first described in 1996.[4] TAZ 
encodes an evolutionarily highly conserved acyltransferase, deficiency of which results 
in defective remodeling of inner mitochondrial membrane phospholipids, especially that 
of cardiolipin (CL). The aetiology of neutropenia in this disease remains the subject of 
debate; researchers postulated that mitochondrial abnormalities could lead to enhanced 
apoptosis of myeloid precursors and neutrophils, although the only published clinical 
study did not demonstrate shortened cell survival despite avid binding of annexin-V to 
BTHS blood neutrophils.[5] However, TAZ knockdown experiments suggest accelerated 
apoptosis of myeloid progenitor cells due to increased dissipation of mitochondrial 
membrane potential, aberrant release of cytochrome c and activation of caspase-3.[6] 
Neutrophil functions, such as directed motility, phagocytosis and killing, appear to be 
unimpaired.[1, 5] 
 
BTHS is still rarely diagnosed, with approximately 200 living males worldwide currently 
known to the Barth Syndrome Foundation, although there is evidence for substantial 
under-diagnosis.[3] To aid in the understanding and diagnosis of this disease, 
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particularly with reference to patterns of neutropenia and associated infection risk, we 
reviewed clinical data, routine blood counts and responses to granulocyte colony 
stimulating factor (G-CSF) therapy from 88 affected boys. 
 
METHODS 
 
Patients 
 
Patient data were obtained from the Barth Syndrome Registry, NHS Specialised 
Services Barth Syndrome Service, Royal Hospital for Children, Bristol, UK, Department 
of Pediatrics, University of Florida Health Center, Gainesville FL and the Severe 
Chronic Neutropenia International Registry (SCNIR), University of Washington, Seattle 
WA. Patients or their parents or guardians gave consent for these studies as approved 
by the respective review boards. Retrospective clinical data were sourced from a 
combination of hospital notes and parental questionnaires. 
 
BTHS was diagnosed through a combination of characteristic clinical features 
(predominantly cardiomyopathy and myopathy) and detection of excessive 3-MGC in 
urine. All were confirmed as having causative mutation of the TAZ gene (Barth 
Syndrome Registry data). Clinical data on illness and infections were gathered through 
chart reviews, patient questionnaires and annual reports of patients in the SCNIR. 
Complete blood counts (CBC) were examined from three sources: (a) the biennial Barth 
Syndrome Foundation International Scientific, Medical and Family conferences, (b) the 
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clinics of the UK national Barth Syndrome Service or (c) patients’ local hospital clinics. 
Seventeen neutropenic males underwent a bone marrow examination. 
 
Mathematical Analysis 
The Lomb periodogram was used to test for statistical significance periodicity in blood 
cell counts.[7-9] 
 
RESULTS 
 
Clinical Characteristics 
The frequency of common disease characteristics is shown in Table 1. Of those patients 
showing DCM, 68% manifested symptoms of cardiomyopathy in the first year of life.   
 
Incidence and Severity of Neutropenia 
Absolute neutrophil counts (ANC) were recorded in all 88 patients at first visit to one of 
the BTHS clinics. The first recorded CBC of 51 (58%) patients revealed an ANC ≤ 1.5 x 
109/L.  Follow-up records revealed that 74 of 88 subjects (84%) had at least one ANC < 
l.5 x 109/L, 28 of whom (38%) had a mean ANC < 1.5 x 109/L.  
 
Multiple CBCs (two or more counts) were available in 79 of the 88 (90%) patients, 44% 
of whom met the criteria for severe chronic neutropenia (SCN), with multiple ANCs < 0.5 
x 109/L over greater than three months. Table 2 shows the data on neutropenia 
frequency in more detail.  
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Fifty-two patients had more than 10 CBCs; 15 of 52 never received G-CSF. The 
distribution of ANCs in these 15 patients is shown in Figure 1A. Despite not receiving G-
CSF, some showed wide amplitude of ANC, e.g. UPN1 with a range of 0.05-9.24 x 
109/L in 63 counts (median 1.74). 
 
Fourteen of the 88 patients (16%) were not neutropenic on any of their CBCs (1-33 
ANCs performed over 0-12.3 years). Mean ANCs in the 14 non-neutropenic patients 
ranged from 1.95-5.28 x 109/L. Twelve of these 14 (86%) non-neutropenic BTHS 
patients exhibited severe DCM. One other boy (UPN36) who presented with severe 
DCM was only mildly neutropenic once (ANC 1.35 x 109/L) from 72 CBCs taken over 
9.58 years. 
 
Monocytosis 
Monocytosis (defined as an absolute monocyte count of greater than 1.0 x 109/L) was 
frequent, recorded at some stage in 64/85 patients (75%) with available monocyte 
counts. Twenty-three of the 64 patients (36%) had absolute monocyte counts of >3.0 x 
109/L on at least one occasion, with the highest monocyte count being 9.69 x 109/L. Fifty 
of 85 patients (59%) had a monocyte count greater than 1.0 x 109/L at the time of 
neutropenia (ANC< 1.5 x 109/L); 13 of the 50 patients (26%) had a monocyte count 
greater than 3.0 x 109/L at the time of neutropenia. Seven of the 14 non-neutropenic 
patients (50%) also had monocyte counts greater than 1.0 x 109/L; one patient had two 
counts >3.0 x 109/L. 
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Difference in incidence and severity of neutropenia occurred among affected family 
members (Figure 1B, UPN35, 36 and 46). ANCs in members of this family did not 
correlate with their severity of cardiomyopathy, proximal myopathy or other symptoms. 
The severity of neutropenia sometimes changed with time. For example UPN9 (who has 
never received G-CSF) had a neutrophil count less than 1.0 x 109/L on 5 of 10 counts 
(median 0.95 x 109/L, range 0.3-1.76 x 109/L) performed serially at age 2-5 months, 1 of 
8 counts (median 1.25 x 109/L, range 0.7-2.5 x 109/L ) performed serially at 4.75 years, 
yet none of 17 counts (median 1.3 x 109/L , range 1.1-1.9 x 109/L) taken over 6 weeks at 
9.5 years and 4 of 21 counts at 12.5 years (median 1.28 x 109/L, range 0.45 – 2.99 x 
109/L).  
 
Rhythmic Fluctuations & Cyclic Neutropenia 
Twenty-seven patients had serial blood counts before G-CSF and eight of the 27 had at 
least 21 counts, giving an adequate period of blood count profiling for assessment of 
cyclic neutropenia. Seven boys appeared to have oscillation of blood neutrophils, four of 
whom are shown in Figure 2 A, C & D and Figure 3A.  
 
Only one boy (UPN10, Figure 3A) satisfied strict mathematical criteria for cyclic 
neutropenia. His cycle length ranged from 21 to 29 days with a mean of 23.3 days. It 
was not clear what effect G-CSF had on cycle duration due to experimentation with 
dosage and frequency of drug following initiation. In UPN37 (Figure 2A) aphthous 
ulceration occurred at nadirs of ANC during the period of study with an average cycle 
length of 25 days (range 23-28), although this patient did not satisfy mathematical 
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criteria for cyclical neutropenia. Serial counts in two brothers suggested cycling at 
shorter time intervals, i.e., 10 days (range 8-13) and 9 days (6-13), respectively 
(UPN35, Figure 2C) and above (UPN36, Figure 2D), but these patterns were not 
apparent on repeat profiles on either boy performed three years later (data not shown). 
 
Bone Marrow Characteristics 
Bone marrow results were available from 19 tests performed in 17 patients. Six patients 
were tested before commencing G-CSF. The remaining aspirates comprised 
surveillance tests taken to exclude development of myelodysplasia or leukaemia 
secondary to G-CSF therapy.  
 
The aspirate or biopsy was reported to be hypocellular in three patients; the remainder 
had normal or had only a modest reduction in cellularity. One patient had mild red cell 
dysplastic change after four years of G-CSF therapy. None of the marrows obtained on 
G-CSF showed an increase in marrow myeloblasts and no clonal cytogenetic change 
was detected. 
 
Decreased myeloid maturation was reported for five of six patients prior to G-CSF 
therapy.  The common abnormality was a relative paucity of mature neutrophils in the 
marrow.  One patient was reported to have an arrest at the metamyelocyte stage; the 
others primarily had reduced numbers of mature neutrophils in the marrow. None of the 
aspirates were described as showing promyelocyte arrest.  
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Results were available on 13 patients investigated during G-CSF therapy. Seven 
marrows showed normalisation of myeloid differentiation, the remaining marrows still 
showing left-shifted myelopoiesis. Marrow cellularity increased in two of three patients 
who had marrows performed both before and on treatment with G-CSF. Increased or 
toxic granulation was observed in two patients. 
 
Increased eosinophils or eosinophil precursors were reported for two of six patients 
prior to G-CSF therapy and six of 13 patients on therapy, one of whom had increased 
eosinophils prior to receiving G-CSF.   
 
Responses to G-CSF 
G-CSF was administered to 39 of 88 subjects (44%). Responses to G-CSF are 
illustrated in Figure 3. Some patients were treated just to cover periods of infection or 
mouth ulceration but in most G-CSF was given on a dosing schedule varying from daily 
to weekly, the most common regimes being three times weekly or alternate daily. For 17 
patients receiving G-CSF on whom detailed data were available, doses averaged over a 
week ranged from 0.12 mcg/kg/day to 10.92 mcg/kg/day (mean 1.160 mcg/kg/day, 
median 1.160 mcg/kg/day). Each of these treated patients had previously exhibited 
severe symptomatic neutropenia. For this group of 17 patients, the median absolute 
neutrophil count pre-G-CSF therapy was 0.47 x 109/L and mean 0.57 x 109/L (range 
0.00-10.45 x 109/L) compared with median ANC of 2.28 x 109/L, mean ANC of 3.93 x 
109/L (range 0.00-33.89 x 109/L) during G-CSF therapy (p< 0.001, paired two tailed T 
test).  
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Determining a dose of G-CSF that alleviated symptoms without producing excessively 
high counts was a problem in some patients due to the wide amplitude of ANC prior to 
treatment. Figure 4A and B show two examples of patients with marked responses to G-
CSF. Careful titration of G-CSF dose (exemplified by UPN10, Figure 3A) and alternate 
daily or thrice weekly dosing prevented excessive rises in neutrophil counts in most 
patients.  
 
Infection Risk 
A detailed review for significant bacterial infections was conducted in 35 patients under 
the longitudinal care of the UK NHS Barth Syndrome Service because all retrospective 
notes could be accessed in this group. Infections  prior to introduction of G-CSF therapy 
included Streptococcal bacteremia/septicemia (2 patients, one resulting in acute tubular 
necrosis), Haemophilus septicemia (one patient, resulting in renal failure requiring renal 
transplantation), osteomyelitis (2 patients), septic arthritis (1), soft tissue abscesses (3), 
cellulitis (5), balanitis (2) lobar consolidation/pneumonia (4), gingivitis (2), severe 
recurrent aphthous ulceration (2), urinary tract infections (1) and secondary infection of 
an underlying keratosis pilaris rash (1). A further UK patient who predeceased this study 
had neutropenia and skin sepsis; he developed severe neurological handicap 
secondary to streptococcal septicemia. The overall registry data also identified further 
instances of streptococcal septicemia (1), pneumococcal bacteremia (1), Haemophilus 
septicemia (1) and Pseudomonas cellulitis (1) and four unspecified episodes of 
bacteremia/septicemia.  
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26 of these 35 UK (74%) patients had one or more counts in the severe neutropenic 
range, 14 (40%) having an ANC of zero on occasions. Of these 26 patients with severe 
neutropenia, 14 (54%) had experienced severe bacterial infections thought to be 
secondary to their underlying neutropenia.  
 
Only five patients in the entire group had significant instances of suspected/proven 
bacterial infection after institution of G-CSF ± antibiotic prophylaxis. One patient died of 
sepsis after suffering recurrent staphylococcal infections, Candidaemia (C. 
parapsillosis) and Enterobacter cloacae infection associated with multiple indwelling 
central venous catheters, an implantable cardioverter defibrillator (ICD) and extensive 
granulation tissue which formed around long-term gastrostomies. He also required 
omphalectomy due to long-term umbilical inflammation / infection. All infections 
occurred despite consistent prevention of neutropenia by G-CSF therapy and death 
occurred after 15.5 years of G-CSF therapy; there was no evidence of myelodysplastic 
or malignant change on longitudinal bone marrow monitoring. Four other patients 
experienced cellulitis either following trauma such as cat scratches or insect bites (3 
patients) or associated with poor compliance with G-CSF (1). One of these patients also 
had recurrent localised cellulitis at his gastrostomy site, which necessitated closure of 
the gastrostomy, despite consistent G-CSF therapy.  
 
From self-reported data on 68 patients in the Barth Syndrome Registry, other more 
minor infections were seen as follow: ear infections (32%), sinusitis (18%) and urinary 
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tract infections (11%). Thirty-two percent of parents reported that their children had 
been admitted to hospital on one or more occasions for investigation or treatment of 
febrile episodes or proven infections.  
 
Discussion 
 
Originally BTHS was reported as a composite X-linked syndrome of DCM, skeletal 
myopathy, neutropenia and growth delay. More recent data emphasise that motor 
delay, infections, mouth ulcers, fatigue and feeding problems (sometimes requiring tube 
or gastrostomy feeding) are also common features (see Table 1). However, tremendous 
phenotypic diversity and inter-patient variability is apparent (reviewed in detail by Clarke 
et al [3]).  
 
This phenotypic diversity applies profoundly to neutropenia which this series shows can 
vary from being persistent and severe, through widely variable and unpredictable (the 
commonest pattern) to never being neutropenic. No genotype/phenotype correlation 
has been demonstrated for any aspect of this disease and this is perhaps not surprising 
when ANCs can vary widely even in males within a single family (as shown in Figure 
1B). It should be noted that one member of this family (UPN36, ANC shown in Figure 
1B) was minimally neutropenic just once (at 1.35 x 109/L, average ANC 4.08) from 72 
CBCs taken at between 13 months and 11 years of age despite an otherwise severe 
disease phenotype.  
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Rigaud et al report similar findings in a French cohort in terms of initial ANC, percentage 
of patients with at least one neutropenic count and those with a median ANC <0.5 x 
109/L. [10] However, these authors highlighted a correlation between severity of 
neutropenia at diagnosis and prognosis; all four patients in that study with an initial ANC 
≤ 0.5 x 109/L died by the age of three years. By contrast 22 patients in our cohort had an 
initial ANC in the same range but only one death occurred (at 23 years, unrelated to 
infection). It seems likely that wider use of G-CSF in the patients reported in this series 
compared to the French series (44% versus 27%) contributed to this discrepancy. 
 
BTHS neutropenia has often been described as cyclical. Our analysis of this was 
hampered by absence of adequately detailed profiles, i.e., blood counts taken thrice 
weekly for 3-6 weeks, in many patients. However, by stringent mathematic analysis, we 
were able to show definitive cycling behaviour - with an average periodicity of 23.3 days 
- in only one boy (UPN10, Figure 3A). Several other profiles also showed rhythmic 
variation (e.g. that of UPN37 in Figure 2A), which might be easy to confuse with the 
disease cyclic neutropenia. Several boys with BTHS also showed an intermittent pattern 
of severe mouth ulceration and gingivitis when neutropenic, which could add to this 
confusion. Similarly, none of the patients described by Rigaud et al exhibited cyclic 
neutropenia.[10] It is therefore more accurate to describe BTHS patients as having 
variable neutropenia. 
 
Important differential diagnoses include cyclic, severe congenital and idiopathic 
neutropenia. Diagnostic confusion between severe congenital neutropenia (SCN) and 
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BTHS could occur although only rarely; for example, one patient had nine out of 10 
ANC below 0.2 x 109/L over a one-year period. Further features in common between 
SCN and BTHS include monocytosis, myelocyte arrest and eosinophilia or increased 
numbers of eosinophil precursors on blood / marrow examination.[1, 11, 12] 
 
The cases that we have described stress the serious risks of infection in these children. 
Further evidence is provided by the family originally described by Peter Barth [1] and an 
18% fatality rate due to infection in the French national experience: two deaths from 
septic shock and two cardiac deaths during unexplained high fever.[10] However, it is 
intriguing that there were no cases of Clostridial infections in this series (even though 
some children had severe persistent neutropenia) and comparatively few cases of deep 
tissue cellulitis. Gauging the risk of infection is also not easy due to the highly 
unpredictable nature of the neutropenia. As one example, UPN37 had mean neutrophil 
counts of 2.5, 2.17, 2.73, 2.06, 1.59 and 2.21 x 109/L in consecutive periods of two 
years yet developed recurrent aphthous ulceration at the nadirs of counts (at 23-28 day 
intervals, see Figure 2A) in only the last of these periods. This deterioration culminated 
in Haemophilus pneumonia and septicemia, renal failure (requiring paternal allograft), 
gut ischemia and Aspergillus peritonitis after peritoneal dialysis catheter insertion. His 
subsequent G-CSF responses are shown in Figure 4A.  
 
G-CSF usage in Barth syndrome was first reported in 1995.[13] Thirty-nine of the 88 
(44%) patients in the current series have received G-CSF, ranging in frequency from 
daily to weekly but most typically on a three times per week or daily basis. With 
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averaged doses from 0.12 mcg/kg/day to 10.92 mcg/kg/day (mean 1.16 mcg/kg/day), 
many boys/men remained intermittently neutropenic (94% of evaluable patients, 
representative examples can be seen in Figure 3C). However, these patients were free 
of significant infections following introduction of G-CSF ± antibiotic prophylaxis in most 
cases. The notable exception was a man with longstanding severe BTHS 
manifestations requiring gastrostomy feeding for many years, intravenous feeding 
requiring central venous catheters, and placement of an ICD to prevent ventricular 
arrhythmia. He developed severe granulation reactions at gastrostomy sites, 
hypertrophic scars at surgical sites and infections related to central venous catheters 
and an ICD despite good control of neutrophil counts by G-CSF over a prolonged 
period. It is unclear whether some of these were unusual manifestations of BTHS or 
inanition due to prolonged illness.  
 
Four other boys developed cellulitis: related to nail biting and non-compliance with G-
CSF in one patient and suspected cellulitis/reactions of debatable relevance to 
neutropenia following insect bites and cat scratches in two others. The fourth boy 
experienced problems with insect bites and recurrent cellulitis around a gastrostomy 
which eventfully necessitated closure. Some patients reported alleviation of aphthous 
ulceration and reduction in malaise/fatigue although this is hard to evaluate. The French 
experience included two episodes of severe infection (including one episode of septic 
shock) whilst patients were receiving G-CSF therapy.[10] These infections underpin the 
rationale for additional use of antibiotic prophylaxis in a majority of neutropenic UK 
patients within this series. 
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Malignancy has been reported in only two boys with BTHS; single cases of juvenile 
myelomonocytic leukaemia (JMML, personal communication, Dr AB de Sousa) and 
post-cardiac transplant EBV negative T-cell non-Hodgkin lymphoma[14] respectively, 
neither child having received G-CSF. No other cases of myelodysplasia or leukemia 
have been reported or are currently known through the Barth Syndrome Registry or 
SCNIR. Nevertheless, we consider it wise to perform intermittent bone marrow 
assessments whilst experience of this treatment for BTHS remains limited.  
 
Historically, BTHS has been regarded as extremely rare, with only 450 affected cases 
ever proven by genetic analysis worldwide. However, with improved case ascertainment 
and better diagnostic tests now available, a frequency as high as one in 140,000 has 
been suggested.[3] US Pediatric Cardiomyopathy Registry data showed that 3-5% of all 
males with cardiomyopathy had BTHS as their underlying diagnosis (Dr. Jeffrey Towbin, 
personal communication). A 2017 Chinese study, using next generation sequencing to 
investigate males and females with primary cardiomyopathy in a systematic fashion, 
showed that 6.5% of males with LVNC ± DCM had pathogenic TAZ mutations. This 
would imply that most pediatric hematologists working alongside specialist cardiac units 
should expect to meet one or more cases in their career. Considering this, there is 
surprisingly little haematological literature on BTHS.[5, 6, 10, 12, 15, 16, 17, 18, 19] 
 
Historical testing for BTHS often relied on identification of 3-methylglutaconic aciduria 
but this is now recognised to be highly unreliable, with many patients lacking 
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pathological aciduria at initial presentation.[18, 19, 20, 21, 22, 23, 24, 25, 26] A “gold 
standard” biochemical test for BTHS is however now available: the ratio of L4-cardiolipin 
(CL) to its closely related precursor monolysocardiolipin (MLCL) (termed the MLCL/CL 
ratio). This test appears to have 100% specificity and sensitivity and can be performed 
on a blood sample sent by routine post.[27, 28] An intermediate form of BTHS has been 
described recently.[29, 30] This is characterised by less severe CL deficiency but still an 
abnormal ratio due to high levels of MLCL. Interestingly this appears to be associated 
with almost complete absence of neutropenia which may hold clues to elucidating 
pathogenesis if confirmed in more patients. Definitive diagnosis can also be performed 
by identifying a causative mutation in the TAZ gene and TAZ sequencing should be 
included in next generation sequencing / clinical exome analyses designed to 
investigate idiopathic neutropenia.  
 
Conclusions 
 
We recommend that BTHS should be considered within the differential diagnosis of any 
boy with unexplained neutropenia - whether chronic severe, cyclical or intermittent in 
nature. This is most important if neutropenia is accompanied by motor delay, 
myopathy/cardiomyopathy, feeding problems, failure to thrive or suspected 
mitochondrial disease, although presentation with isolated neutropenia can occur 
(because DCM is either absent or subclinical or has completely resolved). Particular 
attention should be paid to boys who lack mutation of ELANE or the glucose-6-
phosphatase, catalytic subunit 3 (G6PC3) gene (where structural heart abnormalities 
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are also present).[31] Based on the clinical data summarized in the report, we 
recommend that neutropenic Barth syndrome males who have recurrent fevers and 
infections should be treated approximately 3 days per week with G-CSF in doses 
sufficient to normalize their ANCs.  Prophylactic antibiotics, e.g., low dose daily penicillin 
V or trimethoprim-sulfamethoxazole may be helpful.  
Bullet Points 
• Barth syndrome is a rare sex-link genetic disorder associated with 
neutropenia that may be chronic, intermittent or cyclic and accompanied 
by infections of varying severity. 
• The susceptibility to infections is due only in part to neutropenia; 
congestive heart failure, nutritional deficiencies and the need for feeding 
tubes add to the risk of infections. 
• Neutropenia in Barth responds to long-term treatment with granulocyte 
colony stimulating factor (G-CSF), usually in low dose given 
subcutaneously daily or every other day.  
• In some patient prophylactic antibiotics may help to prevent serious 
infections.   
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Legends to Figures 
 
Figure 1A. Range of ANC in 15 individual patients with more than 10 individual 
CBC readings who never received G-CSF 
Details are shown of ANCs from CBCs taken principally from times of cardiac review, 
clinic visits and inpatient admissions. The dotted line indicates the threshold for 
neutropenia (ANC <1.5 x 109/L). 
 
Figure 1B. Differences between CBC readings within one family 
UPN35 and 36 are brothers, and UPN46 a maternal cousin with BTHS. The earliest 
DCM occurred in UPN36 who has only been minimally neutropenic (at 1.35 x 109/L) on 
one of 72 CBC tests. By contrast his brother has significant proximal myopathy but only 
mild DCM, yet has intermittent neutropenia down to 0.2 x 109/L. Their cousin (UPN46) 
had a minimum ANC of 0.95 x 109/L from 84 observations taken over 16 years; he has 
never received G-CSF or had a significant bacterial infection despite disease of 
sufficient severity to require cardiac transplantation at 3.5 years of age.  
 
Figure 2. Examples of extensive neutrophil profiles in BTHS patients 
(A and B) UPN37 and 80 respectively did not satisfy mathematical criteria for cycling. 
(A) UPN37 appeared to cycle at an average of 25 days (range 23-28 days). His G-CSF 
response is shown in Figure 4A. (B) UPN48 showed spontaneous variability between an 
ANC of zero and 5.3 x 109/L over a period of 61 days; Unpredictable variation in this 
manner is the most common pattern seen in BTHS patients.  (C and D) Two patients 
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(UPN35 & 36 respectively) exhibited periods of rhythmic “microcycling” over periods 
averaging 8-9 days either around (in C) or above (in D) the threshold of neutropenia. 
 
Figure 3. G-CSF responses 
(A) Neutropenia resolved after treatment with G-CSF in UPN10, the only patient who 
satisfied strict mathematical criteria for cyclical neutropenia, with an average periodicity 
of 23.3 days. Doses of G-CSF were steadily titrated down from 5 to 0.5 mcg/kg/day in 
order to keep ANC above 1.5 x 109/L (note logarithmic scale with ANC ranging up to 
33.9 x 109/L). (B) By contrast, UPN69 continues to show irregular periods of 
neutropenia after commencement of G-CSF at 3mcg/kg/dose three times weekly. (C) 
Effect of G-CSF on range of ANC in 14 other patients (UPN 5, 8, 13, 19, 20, 23, 34, 38, 
39, 40, 41, 44, 58 and 67) with the largest numbers of on- and off-therapy CBC.  
 
Figure 4. Exuberant responses to G-CSF 
(A) UPN37 showed a range of ANC of 0.1 to 5.9 x 109/L in the year before commencing 
G-CSF at 3mcg/kg/dose thrice weekly. His ANC ranged from 0.2 to 79.9 in the 6 weeks 
afterwards, although renal transplantation (required as a consequence of previous 
Haemophilus sepsis) may have contributed to these dramatic changes. By contrast, no 
events occurred in UPN51 (shown in B), whose ANC rose to 64 x 109/L, from a 
maximum ANC of 0.6 x 109/L in nine CBCs taken at regular intervals over the previous 
two months, after G-CSF was introduced at 10 g/kg/day; this necessitated switching to 
alternate daily dosing. 
